Compare LCTX & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | RDIB |
|---|---|---|
| Founded | 1990 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.4M | 241.9M |
| IPO Year | 1996 | 1994 |
| Metric | LCTX | RDIB |
|---|---|---|
| Price | $1.08 | $9.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $5.50 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 3.3K |
| Earning Date | 11-12-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.76 |
| EPS | ★ N/A | N/A |
| Revenue | $14,556,000.00 | ★ $202,988,000.00 |
| Revenue This Year | $4.38 | $15.10 |
| Revenue Next Year | $10.80 | $4.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 53.24 | N/A |
| 52 Week Low | $0.88 | $8.00 |
| 52 Week High | $1.99 | $24.00 |
| Indicator | LCTX | RDIB |
|---|---|---|
| Relative Strength Index (RSI) | 60.39 | 34.31 |
| Support Level | $1.02 | $8.24 |
| Resistance Level | $1.18 | $10.22 |
| Average True Range (ATR) | 0.06 | 0.63 |
| MACD | 0.01 | -0.14 |
| Stochastic Oscillator | 93.44 | 35.78 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.